Trial Profile
A Double-blind, Crossover, Placebo-controlled Study to Compare the Effects of Nighttime Administration of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Fatigue; Insomnia
- Focus Therapeutic Use
- Acronyms DREAM
- 21 Mar 2022 Status changed from recruiting to completed.
- 02 Apr 2021 Planned End Date changed from 31 Mar 2020 to 31 Mar 2022.
- 02 Apr 2021 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2021.